A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF110 in ovarian cancer tumors

Johnny Gutierrez, Gottfried E. Konecny, Kyu Hong, Alexander Burges, Timothy D. Henry, Pier D. Lambiase, Lee Wong Wai, Y. Gloria Meng

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


BACKGROUND: Vascular endothelial growth factor (VEGF), which affects tumor angiogenesis, is expressed as different splice variants, including the major isoforms VEGF165 and VEGF121, and can be cleaved by plasmin to generate VEGF110. The amount of VEGF121 and VEGF110 in biological samples has not been well studied. METHODS: We developed an ELISA that detects VEGF165 and VEGF121 equally, but does not detect VEGF110. We used this ELISA together with 2 other ELISAs, one detecting VEGF165 and the other detecting VEGF165, VEGF121, and VEGF110 equally, to assess the concentrations of VEGF121 and VEGF110 in ovarian cancer tumors. RESULTS: The median concentrations in ovarian cancer tumor lysates were 0.61 (range <0.055-74) fmol/mg protein for VEGF 165, 1.4 (range <0.20 -500) fmol/mg protein for VEGF165 plus VEGF121, and 2.3 (range <0.079 -520) fmol/mg protein for total VEGF including VEGF110 (n = 248). VEGF concentrations measured by the 3 ELISAs were highly correlated (r = 0.91-0.94). Median estimated VEGF121 and VEGF110 concentrations were 0.77 and 0.58 fmol/mg protein, respectively. In lysates with measurable VEGF165 and total VEGF concentrations, mean VEGF165 was approximately 31% (SD 23%) of the total VEGF (n = 217). In contrast, VEGF165 constituted approximately half of the total circulating VEGF. CONCLUSION: VEGF 165, VEGF121, and VEGF110 may be present at significant amounts in ovarian cancer tumors.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalClinical chemistry
Issue number3
StatePublished - Mar 1 2008

Fingerprint Dive into the research topics of 'A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF<sub>110</sub> in ovarian cancer tumors'. Together they form a unique fingerprint.

Cite this